What to do: If you have an allergy to milk, do not consume the recalled products
Audience: General public
Recall class: Class 1
Affected products
Brand
Product
Size
UPC
Codes
Searay
Sauerkraut Fish (Szechuan Style) Spicy
400 g
8 27510 00494 2
Best Before: 2022 JL 02 Lot number: 2101181CHG
Searay
Sauerkraut Fish (Golden Soup)
400 g
8 27510 00493 5
Best Before: 2022 JN 15 Lot number: 2012202CHG
Best Before: 2022 JL 02 Lot number: 2101182CHG
Issue
The recall notification issued on February 4, 2022, has been updated to a Food Recall Warning due to additional information. This additional information was identified during the Canadian Food Inspection Agency's food safety investigation.
Searay Foods Inc. is recalling Searay brand Sauerkraut Fish (Szechuan Style) Spicy and Sauerkraut Fish (Golden Soup) from the marketplace because they may contain milk which is not declared on the label.
The recalled products have been sold in Alberta, British Columbia, Manitoba, Nova Scotia, Ontario, Quebec, and Saskatchewan and may have been distributed in other provinces and territories.
What you should do
Check to see if you have the recalled products in your home
If you have an allergy to milk, do not consume the recalled products as they may cause a serious or life-threatening reaction
Recalled products should be thrown out or returned to the location where they were purchased
This recall was triggered by Canadian Food Inspection Agency test results.
There have been no reported reactions associated with the consumption of these products.
What is being done
The Canadian Food Inspection Agency (CFIA) is conducting a food safety investigation, which may lead to the recall of other products. If other high-risk products are recalled, the CFIA will notify the public through updated food recall warnings.
The CFIA is verifying that industry is removing the recalled products from the marketplace.
Genexine (KOSDAQ: 095700), a publicly-listed, clinical-stage Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of serious unmet medical needs, announced a merger with EPD Biotherapeutics...
The IAMStm brand, proudly part of the Mars family of brands, announced today the launch of the IAMStm Puppy Hub and Kitten Hub, two online tools featuring expert knowledge and advice for new and soon-to-be pet parents. Each Hub will bring...
Today, TELUS Health announced a collaboration with Nova Scotia Health (NSH) to enable residents of Nova Scotia to access their primary care information through the YourHealthNS app. This health data interoperability initiative marks the first...
The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to...
Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The...
Calliditas Therapeutics AB (STO: CALTX) ("Calliditas") today announces that its partner Viatris Pharmaceutical Japan G.K. ("Viatris") has initiated a phase III clinical trial in Japan with Nefecon, named VR-205 in the Japanese market, in Japanese...